Agilent Technologies Inc. - A STOCK NEWS

Agilent Technologies reported a strong second quarter with revenue of $1.61 billion, reflecting a 5% increase year-over-year and 7% growth on a core basis. GAAP net income rose to $274 million or 91 cents per share, marking a 30% increase from Q2 2021. Non-GAAP earnings reached $340 million with an EPS of $1.13, up 16% year-over-year. The company raised its full-year revenue guidance to between $6.67 billion and $6.73 billion, projecting core growth of 8% to 9% and non-GAAP EPS of $4.86 to $4.93.

Agilent Technologies (NYSE: A) has declared a quarterly dividend of 21 cents per share, payable on July 27, 2022, to shareholders of record as of July 5, 2022. The future timing and amount of dividends will be subject to approval by Agilent's board of directors. This press release also includes forward-looking statements regarding the company's dividend program and future obligations, which may be affected by various risks and uncertainties. Agilent generated revenue of $6.32 billion in fiscal 2021, employing approximately 17,000 people globally.

Agilent Technologies (NYSE: A) announced that its PD-L1 IHC 22C3 pharmDx is now CE-IVD-marked for use in cervical cancer in Europe. This diagnostic aids in identifying patients eligible for treatment with KEYTRUDA (pembrolizumab), an anti-PD-1 therapy developed by Merck. Cervical cancer is notably prevalent, with approximately 30,447 new cases in Europe in 2020. This expansion allows pathologists to access reliable testing for more patients, enhancing Agilent's position in the diagnostics market for targeted cancer therapies.

Agilent Technologies Inc. (NYSE: A) will release its financial results for the second quarter of fiscal year 2022 on May 24, 2022, after market close. A live webcast of the investor conference call will be held on the same day at 1:30 p.m. PT. Agilent, a leader in life sciences and diagnostics, reported $6.32 billion in revenue for fiscal 2021 and has approximately 17,000 employees globally. A replay of the webcast will be available for 90 days on the company’s investor relations website.

Agilent Technologies Inc. (NYSE: A) has joined the National Institute for Innovation in Manufacturing to Advance Biomanufacturing (NIIMBL), reinforcing its commitment to biopharmaceutical innovation. This partnership aims to enhance continuous manufacturing solutions, improve supply chain logistics, and increase accessibility to biotherapeutics. CEO Mike McMullen emphasized the growing importance of innovative measurement tools for delivering life-saving drugs. Agilent's advanced technologies, such as online HPLC sampling and real-time sensors, will play a vital role in shaping future bioprocess development.

Agilent Technologies (NYSE: A) announced advancements in cancer research at the American Association for Cancer Research Annual Meeting in New Orleans from April 8-13, 2022. The company showcased its innovative products like the Agilent Magnis NGS Prep System, allowing rapid assay setups, and the XF Pro Analyzer for live cell monitoring. Agilent's commitment to cancer research aims to support researchers with a comprehensive toolkit for diagnostics and therapeutic development. In fiscal 2021, Agilent generated $6.32 billion in revenue and has a global workforce of 17,000.

Agilent Technologies Inc. (NYSE: A) has received CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx assay. This approval allows use in patients with muscle-invasive urothelial carcinoma (MIUC) who exhibit tumor cell PD-L1 expression ≥ 1%, specifically for adjuvant treatment with OPDIVO® (nivolumab). Urothelial carcinoma poses a significant health burden, with 500,000 new cases globally and a 50% relapse rate in MIUC patients. This development enhances treatment options for high-risk patients and underscores Agilent's commitment to advancing diagnostic solutions.

Agilent Technologies Inc. (NYSE: A) announced expanded CE-IVD marking in the EU for its PD-L1 IHC 28-8 pharmDx, aiding in identifying esophageal squamous cell carcinoma patients for treatment with OPDIVO® (nivolumab) alongside chemotherapy or YERVOY® (ipilimumab). Esophageal cancer, the seventh most common globally, had about 600,000 new cases in 2020. This advancement marks a significant step in providing targeted immunotherapy options, promising improved survival rates for patients.

Agilent Technologies Inc. (NYSE: A) has joined the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC), highlighting its commitment to enhancing biopharmaceutical manufacturing processes. This partnership aims to advance analytical tools and solutions critical for biotherapeutics and gene therapy. Senior VP Darlene Solomon emphasized the need for improved biomanufacturing efficiencies. Agilent's innovations in automation, machine learning, and real-time analytics will support these efforts, contributing to lower costs and improved bioprocessing efficiency in the biopharmaceutical sector.